2026 NPPES data Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician NPI 1245433259 MD
Verify on CMS →

MARK DACEY, MD

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in DENVER, Colorado. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
2K
Medicare Part D claims · 309 beneficiaries · Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician avg: 642
Generic prescribing
67%
generic claims · 33% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
100/100
▲ 17 pts above national avg 83.1 · [object Object]
Industry payments
$119.6K
83 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

MARK DACEY, MD reported a CMS MIPS final score of 100/100 — above the 83.1 national average — and filed 1,946 Medicare Part D claims in 2023.

100/100
MIPS score · +17 vs avg
2K
Part D claims, 2023
67%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

MARK DACEY, MD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

100 Top 7% higher than 93% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

MARK DACEY, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about MARK DACEY, MD?

High performer (top quartile)

NPI registry status

Active

Issued 06/07/2007

NPI 1245433259

Primary specialty

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician

Rare

37 US NPIs in this specialty

Medicare Part D claims

1,946 203% vs specialty avg

2023 prescription claims

Specialty avg: 642

MIPS final score

100/100 16.900000000000006% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in Colorado

How Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician compares to other specialties among Colorado providers

Colorado providers

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician share within Colorado

1. Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician share within Colorado

Medicare quality performance — MIPS

MARK DACEY, MD's 2023 MIPS final score plotted against the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician national average

High performer (top quartile)
MIPS Final Score
100/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) — 100/100 vs national avg 83.1

0%100%National avg83%99%
MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) — 100/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARK DACEY, MD appears in the CMS NPPES registry as a Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider holding MD credentials at 425 S CHERRY ST STE 907, DENVER, CO, 80246, with a listed phone of (208) 266-4227. NPI 1245433259 was issued on 06/07/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what DACEY most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,946 prescription claims written by this provider, covering 309 Medicare beneficiaries and totaling roughly $1.4 million in drug spend, split 33% brand-name and 67% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 100), compared with the national average of 83.1.

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is a narrow specialty nationwide, with 37 enrolled providers across 15 states and an average of 642 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

425 S CHERRY ST STE 907
DENVER, CO 80246

Provider Details

NPI 1245433259
Specialty Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
Credentials MD
Gender Male
NPI Issued 06/07/2007

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

100
Final Score
Avg: 83.1
100
Quality

Reporting: Group practice

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARK DACEY, MD. Source: openpaymentsdata.cms.gov.

Total received

$119.6K

Largest payer

Alimera Sciences, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Above average

MARK DACEY, MD — brand share 33.0%
Specialty average (est.)

33% brand-name claims vs 67% generic, on 1,946 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,946
Total Claims
$1.4M
Total Drug Cost
309
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
2,913
Total Day Supply
81,390
Brand vs Generic
33% brand / 67% generic
Brand Drug Cost
$1.3M
Generic Drug Cost
$108K
Antibiotic Claims
18

Patient Demographics

Average Patient Age
72.9 years
Avg HCC Risk Score
1.40
Gender Split
65% female / 35% male
Age Distribution
<65: 31, 65-74: 145, 75-84: 105, 85+: 28

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What MARK DACEY, MD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Prednisolone Acetate
261
Difluprednate
205
Methotrexate
Methotrexate Sodium
169
Timolol Maleate
138
Mycophenolate Mofetil
107
Latanoprost
91
Brimonidine Tartrate
89
Humira(Cf) Pen
Adalimumab
89
Prednisone
87
Valacyclovir
Valacyclovir Hcl
79

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Overview

How MARK DACEY, MD fits within the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician landscape nationally.

37
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in US
15
States with Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
642
Avg Claims per Provider

MARK DACEY, MD's 1,946 claims are above the specialty average of 642.

Frequently Asked Questions

What is MARK DACEY, MD's specialty?
MARK DACEY, MD specializes in Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician and practices in DENVER, Colorado. Credentials: MD.
How much does MARK DACEY, MD prescribe under Medicare Part D?
In 2023, MARK DACEY, MD wrote 1,946 Medicare Part D claims totaling $1.4M in drug costs for 309 beneficiaries.
What is MARK DACEY, MD's Medicare quality score?
MARK DACEY, MD has a CMS MIPS Final Score of 100/100 (Quality: 100). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MARK DACEY, MD located?
MARK DACEY, MD is located at 425 S CHERRY ST STE 907, DENVER, CO, 80246. Phone: (208) 266-4227.
What is MARK DACEY, MD's NPI number?
MARK DACEY, MD's National Provider Identifier (NPI) is 1245433259, issued on 06/07/2007.
Does MARK DACEY, MD prescribe more brand-name or generic drugs?
MARK DACEY, MD's prescribing is 33% brand-name and 67% generic drugs by claim count, with $1.3M in brand drug costs.
How many Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers are there in the US?
There are 37 Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers across 15 states in the US. The average Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider writes 642 Medicare Part D claims per year.
What drugs does MARK DACEY, MD prescribe most often?
Based on 2023 Medicare Part D data, MARK DACEY, MD's most frequently prescribed drugs include Prednisolone Acetate, Difluprednate, Methotrexate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARK DACEY, MD accept Medicare?
MARK DACEY, MD appears in CMS Medicare data with 1,946 Part D claims and 309 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARK DACEY, MD's credentials?
MARK DACEY, MD's NPI is 1245433259 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology